Literature DB >> 16330682

The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation.

D Dobrev1, A Friedrich, N Voigt, N Jost, E Wettwer, T Christ, M Knaut, U Ravens.   

Abstract

BACKGROUND: The molecular mechanism of increased background inward rectifier current (IK1) in atrial fibrillation (AF) is not fully understood. We tested whether constitutively active acetylcholine (ACh)-activated I(K,ACh) contributes to enhanced basal conductance in chronic AF (cAF). METHODS AND
RESULTS: Whole-cell and single-channel currents were measured with standard voltage-clamp techniques in atrial myocytes from patients with sinus rhythm (SR) and cAF. The selective I(K,ACh) blocker tertiapin was used for inhibition of I(K,ACh). Whole-cell basal current was larger in cAF than in SR, whereas carbachol (CCh)-activated I(K,ACh) was lower in cAF than in SR. Tertiapin (0.1 to 100 nmol/L) reduced I(K,ACh) in a concentration-dependent manner with greater potency in cAF than in SR (-logIC50: 9.1 versus 8.2; P<0.05). Basal current contained a tertiapin-sensitive component that was larger in cAF than in SR (tertiapin [10 nmol/L]-sensitive current at -100 mV: cAF, -6.7+/-1.2 pA/pF, n=16/5 [myocytes/patients] versus SR, -1.7+/-0.5 pA/pF, n=24/8), suggesting contribution of constitutively active I(K,ACh) to basal current. In single-channel recordings, constitutively active I(K,ACh) was prominent in cAF but not in SR (channel open probability: cAF, 5.4+/-0.7%, n=19/9 versus SR, 0.1+/-0.05%, n=16/9; P<0.05). Moreover, IK1 channel open probability was higher in cAF than in SR (13.4+/-0.4%, n=19/9 versus 11.4+/-0.7%, n=16/9; P<0.05) without changes in other channel characteristics.
CONCLUSIONS: Our results demonstrate that larger basal inward rectifier K+ current in cAF consists of increased IK1 activity and constitutively active I(K,ACh). Blockade of I(K,ACh) may represent a new therapeutic target in AF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330682     DOI: 10.1161/CIRCULATIONAHA.105.575332

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  137 in total

Review 1.  Genetic defects in the hotspot of inwardly rectifying K(+) (Kir) channels and their metabolic consequences: a review.

Authors:  Bikash R Pattnaik; Matti P Asuma; Ryan Spott; De-Ann M Pillers
Journal:  Mol Genet Metab       Date:  2011-10-19       Impact factor: 4.797

2.  The Role of Inhibitory G Proteins and Regulators of G Protein Signaling in the in vivo Control of Heart Rate and Predisposition to Cardiac Arrhythmias.

Authors:  Richard Ang; Aaisha Opel; Andrew Tinker
Journal:  Front Physiol       Date:  2012-04-24       Impact factor: 4.566

3.  G protein-gated IKACh channels as therapeutic targets for treatment of sick sinus syndrome and heart block.

Authors:  Pietro Mesirca; Isabelle Bidaud; François Briec; Stéphane Evain; Angelo G Torrente; Khai Le Quang; Anne-Laure Leoni; Matthias Baudot; Laurine Marger; Antony Chung You Chong; Joël Nargeot; Joerg Striessnig; Kevin Wickman; Flavien Charpentier; Matteo E Mangoni
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-01       Impact factor: 11.205

Review 4.  Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective.

Authors:  Stanley Nattel; Jordi Heijman; Liping Zhou; Dobromir Dobrev
Journal:  Circ Res       Date:  2020-06-18       Impact factor: 17.367

Review 5.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

Review 6.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

7.  Voltage-dependent open-channel block of G protein-gated inward-rectifying K(+) (GIRK) current in rat atrial myocytes by tamoxifen.

Authors:  Svenja Vanheiden; Lutz Pott; Marie-Cécile Kienitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-25       Impact factor: 3.000

8.  Regulation of the SK3 channel by microRNA-499--potential role in atrial fibrillation.

Authors:  Tian-You Ling; Xiao-Li Wang; Qiang Chai; Tin-Wah Lau; Celeste M Koestler; Soon J Park; Richard C Daly; Kevin L Greason; Jin Jen; Li-Qun Wu; Wei-Feng Shen; Win-Kuang Shen; Yong-Mei Cha; Hon-Chi Lee
Journal:  Heart Rhythm       Date:  2013-03-14       Impact factor: 6.343

9.  Novel pharmacological approaches for antiarrhythmic therapy.

Authors:  Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-01-15       Impact factor: 3.000

10.  Dominant frequency increase rate predicts transition from paroxysmal to long-term persistent atrial fibrillation.

Authors:  Raphael P Martins; Kuljeet Kaur; Elliot Hwang; Rafael J Ramirez; B Cicero Willis; David Filgueiras-Rama; Steven R Ennis; Yoshio Takemoto; Daniela Ponce-Balbuena; Manuel Zarzoso; Ryan P O'Connell; Hassan Musa; Guadalupe Guerrero-Serna; Uma Mahesh R Avula; Michael F Swartz; Sandesh Bhushal; Makarand Deo; Sandeep V Pandit; Omer Berenfeld; José Jalife
Journal:  Circulation       Date:  2014-01-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.